| Characteristic . | NT1 . | NT2 . | ||
|---|---|---|---|---|
| ON-SXB n = 80 . | Placebo n = 82 . | ON-SXB n = 27 . | Placebo n = 23 . | |
| Mean age (range), y | 32.1 (16–72) | 32.2 (16–67) | 27.4 (16–45) | 29.3 (16–69) |
| Median BMI (range), kg/m2 | 27.8 (17.7–71.9) | 26.9 (18.1–46.5) | 23.8 (16.9–37.0) | 25.6 (18.8–43.2) |
| Sex,n(%) | ||||
| Female | 55 (68.8) | 63 (76.8) | 14 (51.9) | 12 (52.2) |
| Male | 25 (31.3) | 19 (23.2) | 13 (48.1) | 11 (47.8) |
| Race,n(%) | ||||
| White | 62 (77.5) | 62 (75.6) | 18 (66.7) | 18 (78.3) |
| Black/African American | 15 (18.8) | 14 (17.1) | 6 (22.2) | 1 (4.3) |
| Asian | 1 (1.3) | 5 (6.1) | 2 (7.4) | 3 (13.0) |
| Other | 2 (2.5) | 1 (1.2) | 1 (3.7) | 1 (4.3) |
| Region,n(%) | ||||
| United States | 47 (58.8) | 42 (51.2) | 16 (59.3) | 11 (47.8) |
| Rest of world | 33 (41.3) | 40 (48.8) | 11 (40.7) | 12 (52.2) |
| Characteristic . | NT1 . | NT2 . | ||
|---|---|---|---|---|
| ON-SXB n = 80 . | Placebo n = 82 . | ON-SXB n = 27 . | Placebo n = 23 . | |
| Mean age (range), y | 32.1 (16–72) | 32.2 (16–67) | 27.4 (16–45) | 29.3 (16–69) |
| Median BMI (range), kg/m2 | 27.8 (17.7–71.9) | 26.9 (18.1–46.5) | 23.8 (16.9–37.0) | 25.6 (18.8–43.2) |
| Sex,n(%) | ||||
| Female | 55 (68.8) | 63 (76.8) | 14 (51.9) | 12 (52.2) |
| Male | 25 (31.3) | 19 (23.2) | 13 (48.1) | 11 (47.8) |
| Race,n(%) | ||||
| White | 62 (77.5) | 62 (75.6) | 18 (66.7) | 18 (78.3) |
| Black/African American | 15 (18.8) | 14 (17.1) | 6 (22.2) | 1 (4.3) |
| Asian | 1 (1.3) | 5 (6.1) | 2 (7.4) | 3 (13.0) |
| Other | 2 (2.5) | 1 (1.2) | 1 (3.7) | 1 (4.3) |
| Region,n(%) | ||||
| United States | 47 (58.8) | 42 (51.2) | 16 (59.3) | 11 (47.8) |
| Rest of world | 33 (41.3) | 40 (48.8) | 11 (40.7) | 12 (52.2) |
BMI, body mass index; NT1, narcolepsy type 1; NT2, narcolepsy type 2; ON-SXB, once-nightly sodium oxybate (FT218).
| Characteristic . | NT1 . | NT2 . | ||
|---|---|---|---|---|
| ON-SXB n = 80 . | Placebo n = 82 . | ON-SXB n = 27 . | Placebo n = 23 . | |
| Mean age (range), y | 32.1 (16–72) | 32.2 (16–67) | 27.4 (16–45) | 29.3 (16–69) |
| Median BMI (range), kg/m2 | 27.8 (17.7–71.9) | 26.9 (18.1–46.5) | 23.8 (16.9–37.0) | 25.6 (18.8–43.2) |
| Sex,n(%) | ||||
| Female | 55 (68.8) | 63 (76.8) | 14 (51.9) | 12 (52.2) |
| Male | 25 (31.3) | 19 (23.2) | 13 (48.1) | 11 (47.8) |
| Race,n(%) | ||||
| White | 62 (77.5) | 62 (75.6) | 18 (66.7) | 18 (78.3) |
| Black/African American | 15 (18.8) | 14 (17.1) | 6 (22.2) | 1 (4.3) |
| Asian | 1 (1.3) | 5 (6.1) | 2 (7.4) | 3 (13.0) |
| Other | 2 (2.5) | 1 (1.2) | 1 (3.7) | 1 (4.3) |
| Region,n(%) | ||||
| United States | 47 (58.8) | 42 (51.2) | 16 (59.3) | 11 (47.8) |
| Rest of world | 33 (41.3) | 40 (48.8) | 11 (40.7) | 12 (52.2) |
| Characteristic . | NT1 . | NT2 . | ||
|---|---|---|---|---|
| ON-SXB n = 80 . | Placebo n = 82 . | ON-SXB n = 27 . | Placebo n = 23 . | |
| Mean age (range), y | 32.1 (16–72) | 32.2 (16–67) | 27.4 (16–45) | 29.3 (16–69) |
| Median BMI (range), kg/m2 | 27.8 (17.7–71.9) | 26.9 (18.1–46.5) | 23.8 (16.9–37.0) | 25.6 (18.8–43.2) |
| Sex,n(%) | ||||
| Female | 55 (68.8) | 63 (76.8) | 14 (51.9) | 12 (52.2) |
| Male | 25 (31.3) | 19 (23.2) | 13 (48.1) | 11 (47.8) |
| Race,n(%) | ||||
| White | 62 (77.5) | 62 (75.6) | 18 (66.7) | 18 (78.3) |
| Black/African American | 15 (18.8) | 14 (17.1) | 6 (22.2) | 1 (4.3) |
| Asian | 1 (1.3) | 5 (6.1) | 2 (7.4) | 3 (13.0) |
| Other | 2 (2.5) | 1 (1.2) | 1 (3.7) | 1 (4.3) |
| Region,n(%) | ||||
| United States | 47 (58.8) | 42 (51.2) | 16 (59.3) | 11 (47.8) |
| Rest of world | 33 (41.3) | 40 (48.8) | 11 (40.7) | 12 (52.2) |
BMI, body mass index; NT1, narcolepsy type 1; NT2, narcolepsy type 2; ON-SXB, once-nightly sodium oxybate (FT218).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
